Pomerantz Law Firm Investigates Potential Fraud at XOMA Royalty Corporation Pomerantz LLP has commenced an investigation into potential securities fraud involving XOMA Royalty Corporation, following disappointing clinical trial results.

Pomerantz Law Firm Investigates Potential Fraud at XOMA Royalty Corporation #United_States #New_York #Clinical_Trials #Pomerantz_LLP #XOMA_Royalty

Investigating LAVA Therapeutics: Are Shareholders Receiving Fair Compensation? The Ademi Firm is examining whether LAVA Therapeutics is adequately compensating its shareholders in its recent purchase agreement amendments, raising concerns over fiduciary duties.

Investigating LAVA Therapeutics: Are Shareholders Receiving Fair Compensation? #USA #Milwaukee #Ademi_Firm #XOMA_Royalty #LAVA_Therapeutics

ESSA Pharma Inc. Modifies Agreement with XenoTherapeutics for Strategic Transactions ESSA Pharma Inc. has amended its agreement with XenoTherapeutics, impacting shareholder returns and transaction terms, now scheduled for discussion.

ESSA Pharma Inc. Modifies Agreement with XenoTherapeutics for Strategic Transactions #ESSA_Pharma #XenoTherapeutics #XOMA_Royalty

Investigation Launched on Mural Oncology plc by Class Action Firm Monteverde & Associates PC is investigating Mural Oncology plc following its sale to XOMA Royalty Corporation. Shareholders may be affected.

Investigation Launched on Mural Oncology plc by Class Action Firm #United_States #New_York #XOMA_Royalty #Monteverde_Law #Mural_Oncology

Monteverde Firm Investigates Fairness of LAVA Therapeutics Sale to XOMA Royalty Corporation Monteverde & Associates PC is probing the proposed acquisition of LAVA Therapeutics N.V. by XOMA Royalty. Is this sale fair for shareholders?

Monteverde Firm Investigates Fairness of LAVA Therapeutics Sale to XOMA Royalty Corporation #United_States #New_York #Class_Action #XOMA_Royalty #LAVA_Therapeutics

ESSA Pharma Inc. Finalizes Definitive Acquisition Agreement with XenoTherapeutics and XOMA Royalty Corporation ESSA Pharma Inc. has entered a definitive acquisition agreement with XenoTherapeutics, supported by XOMA Royalty Corporation, promising cash value to shareholders.

ESSA Pharma Inc. Finalizes Definitive Acquisition Agreement with XenoTherapeutics and XOMA Royalty Corporation #USA #ESSA_Pharma #South_San_Francisco #XenoTherapeutics #XOMA_Royalty